The current state and future prospects of chronic hepatitis C virus infection treatment.

摘要: Hepatitis C virus (HCV) infection is a significant cause of chronic liver disease with substantial long-term sequelae. Until very recently, therapies to cure HCV were hindered by high nonresponse rates and severe side effects. The first-generation protease inhibitor-containing regimens provided superior for many HCV-infected patients, although their side-effect profile proved be quite burdensome. We are now witnessing the emergence rates, limited effects, broad genotypic activity. Two therapies, sofosbuvir (an NS5b polymerase inhibitor) simeprevir (a second-generation NS3/4A inhibitor), approved Food Drug Administration in late 2013 use number populations. This review focuses primarily upon these key studies that support practice. Furthermore, representative novel antiviral advanced stages testing, also reviewed.